Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483716 | 0.87 | NPY1R (0.38) | LTB4R2MMP3CTSKAGTR1MME | |
| SCHEMBL6480351 | 0.86 | CA2 (0.32) | LTB4R2MMP3CTSKAGTR1AGTR2 | |
| SCHEMBL6491914 | 0.85 | F2 (0.45) | SCN9AALDH1A1HTTSMN1; SMN2CA1 | |
| SCHEMBL6481243 | 0.84 | GHSR (0.34) | LTB4R2AGTR1MMEAGTR2 | |
| SCHEMBL6481968 | 0.83 | HDAC8 (0.44) | CTSKHTT | |
| SCHEMBL6491550 | 0.81 | NAMPT (0.34) | LTB4R2SCN9AAGTR1MME | |
| SCHEMBL6481904 | 0.80 | NPY1R (0.41) | LTB4R2AGTR1SPHK1AGTR2NPY1R | |
| SCHEMBL8792328 | 0.79 | NPY1R (0.43) | MMP3CTSKNPY1R | |
| SCHEMBL6482170 | 0.78 | SIRT2 (0.38) | LTB4R2AGTR1NPY1R | |
| SCHEMBL8793511 | 0.77 | NPY1R (0.45) | MMP3NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | LTB4R2 2432/4885MMP3 1747/4885CTSK 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.